Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
FreeMind Investments (FMI) is a Boston-based venture capital fund focused on the life sciences industry, with additional offices in Jerusalem and Seoul. The firm collaborates with strategic and limited partners to invest in research and development initiatives, leveraging expertise from FreeMind Group and Daewoong Pharma. FMI primarily invests in the United States (60%), Europe (30%), and other regions like Israel, Australia, and Canada (10%).
FMI invests in the life sciences sector, particularly in pre-clinical and clinical stage programs. The firm employs a proprietary investment formula that rigorously assesses scientific and business potential through due diligence. Check sizes and specific investment amounts are not disclosed, but the focus remains on identifying high-potential companies for successful exits.
FMI's portfolio includes notable companies such as Abalone Bio, which focuses on bioactive antibodies for immuno-oncology; Vincere Biosciences, researching mitophagy in Parkinson's disease; Thetis Pharmaceuticals, developing an oral drug for inflammatory bowel disease; Renalis Health, creating FDA-cleared digital therapeutics for pelvic health; Tangen Biosciences, known for the TangenDx™ platform for rapid DNA/RNA detection; BioKier, which works on oral products for lipid and glucose management; and BioMarker Strategies, developer of the SnapPath® Cancer Diagnostics System.
To pitch FreeMind Investments, email info@freemindinvestments.com with your deck.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.